BioAtla (NASDAQ:BCAB) Stock Price Up 3.7% – Here’s What Happened

Shares of BioAtla, Inc. (NASDAQ:BCAB) traded up 3.7% on Friday . The company traded as high as $3.80 and last traded at $3.68. 41,216 shares were traded during mid-day trading, a decline of 37% from the average session volume of 65,113 shares. The stock had previously closed at $3.55.

Wall Street Analyst Weigh In

A number of brokerages recently commented on BCAB. Wall Street Zen raised shares of BioAtla to a “hold” rating in a research note on Saturday, April 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioAtla in a report on Wednesday, June 3rd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $200.00.

BioAtla Stock Performance

The business has a 50-day moving average of $4.06 and a 200 day moving average of $11.97. The stock has a market cap of $6.10 million, a PE ratio of -0.09 and a beta of 0.79.

BioAtla (NASDAQ:BCAB) last released its earnings results on Friday, May 15th. The company reported ($4.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($10.00) by $5.78.

Hedge Funds Weigh In On BioAtla

Institutional investors and hedge funds have recently modified their holdings of the company. Woodline Partners LP acquired a new stake in BioAtla during the first quarter worth approximately $26,000. ADAR1 Capital Management LLC raised its holdings in BioAtla by 24.6% in the 1st quarter. ADAR1 Capital Management LLC now owns 228,107 shares of the company’s stock valued at $37,000 after acquiring an additional 45,000 shares during the last quarter. Susquehanna International Group LLP raised its holdings in BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after acquiring an additional 177,760 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of BioAtla by 55.4% during the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after purchasing an additional 123,597 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of BioAtla during the third quarter worth $235,000. Hedge funds and other institutional investors own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical?stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti?tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.